Article
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.
Analytical cellular pathology (Amsterdam) - 1 Jan 2011
Richman Susan D, Chambers Philip, Seymour Matthew T, Daly Catherine, Grant Sophie, Hemmings Gemma, Quirke Philip
Abstract excerpt
KRAS mutation status is established as a predictive biomarker of benefit from anti-EGFr therapies. Mutations are normally assessed using DNA extracted from one formalin-fixed, paraffin-embedded (FFPE) tumor block. We assessed heterogeneity of KRAS and BRAF mutation status intra-tumorally (multiple blocks from the same primary tumor). We also investigated the utility and efficiency of genotyping a 'DNA cocktail'...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.